A Phase 1/2a, Randomized, Double Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD384 in Overweight or Obese Participants
Latest Information Update: 05 May 2026
At a glance
- Drugs SRSD 384 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Sirius Therapeutics
Most Recent Events
- 05 May 2026 New trial record